NCT00092079View on ClinicalTrials.gov

A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)

PHASE3CompletedINTERVENTIONAL
Enrollment

652

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions
OsteoporosisVitamin D Deficiency
Interventions
DRUG

MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092079 - A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) | Biotech Hunter | Biotech Hunter